Every 424B that GENPACT LIMITED (G) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow G and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full G filings page.
Genpact Limited registered 180,845,599 shares of common stock for issuance in connection with a proposed domestication from Bermuda to Delaware. Separately, 167,227,006 common shares were issued and outstanding and entitled to vote as of September 30, 2026. Shareholders will vote at a special meeting on November 10, 2026.
If approved, the Board would have sole discretion to effect the move until the 2028 Annual General Meeting, subject to final Board approval. Completion is expected on or around March 1, 2027, but the Board may delay or abandon it. At effectiveness, each outstanding Bermuda common share would convert into an equivalent Delaware common share, preserving proportional ownership; equity awards would also convert into equivalent awards, generally on the same terms.
Genpact says its business, assets, liabilities, ownership and fiscal year would remain unchanged, with accounting treated as a continuation of the existing reporting entity. Delaware law and the new charter and bylaws would change some shareholder rights, including anti-takeover and exclusive-forum provisions. Genpact expects cost savings but says the effective tax rate could change and expected benefits may not be realized.
Genpact UK Finco plc and Genpact USA, Inc. priced a $350,000,000 offering of 4.950% Senior Notes due 2030, fully and unconditionally guaranteed on a senior unsecured basis by Genpact Limited and Genpact Luxembourg S.à r.l. The notes mature on November 18, 2030 and pay interest semi-annually on May 18 and November 18, starting May 18, 2026.
The notes were offered at 99.593% with a 0.400% underwriting discount, resulting in proceeds before expenses of $347,175,500; Genpact estimates net proceeds of approximately $345.4 million. The company intends to use the net proceeds for general corporate purposes, which may include repaying or redeeming the 1.750% Senior Notes due 2026, of which approximately $350 million is outstanding, at or prior to their April 10, 2026 maturity.
The notes are senior unsecured obligations with optional redemption at a make‑whole premium before October 18, 2030 and at par thereafter, and include a change of control repurchase at 101% of principal. Genpact plans to apply to list the notes on The International Stock Exchange; there is currently no public market.
Genpact UK Finco plc and Genpact USA, Inc. plan a primary offering of senior unsecured notes due 2030, fully and unconditionally guaranteed by Genpact Limited and Genpact Luxembourg S.à r.l. The notes pay interest semi-annually beginning in 2026 and rank pari passu with the issuers’ other senior unsecured debt.
The issuers may redeem the notes at any time before one month prior to maturity at a make‑whole price, and at par thereafter; a change of control repurchase event requires a 101% offer to holders. The issuers intend to apply to list the notes on The International Stock Exchange.
Use of proceeds: general corporate purposes, which may include repaying or redeeming the 1.750% senior notes due 2026; approximately $350 million of those 2026 notes are outstanding. As of September 30, 2025, Genpact had $1.2 billion of unsecured indebtedness outstanding and undrawn revolving credit availability of $648.74 million.